Status:
COMPLETED
Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes
Lead Sponsor:
AstraZeneca
Conditions:
Severe Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-ago...
Detailed Description
This is a real-world retrospective, multicentric, observational study, utilizing secondary data collection from medical records of adults patients (≥18 years) with severe asthma (maintenance treatment...
Eligibility Criteria
Inclusion
- Adults patients with severe asthma treated with benralizumab, who had their first benralizumab dose between July 2019 and October 2020
- Patients who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.
- Give voluntary signed informed consent
Exclusion
- Currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial
Key Trial Info
Start Date :
August 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 3 2022
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT07159295
Start Date
August 10 2021
End Date
November 3 2022
Last Update
October 21 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Prof. Dr. Fernando Fonseca
Amadora, Portugal, 2720-276
2
HSMM
Barcelos, Portugal, 4750-275
3
CHUC - Imunoalergologia
Coimbra, Portugal, 3000 -076
4
CHUC - Pneumologia
Coimbra, Portugal, 3000 -076